Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In a phase III trial, the addition of obinutuzumab to standard therapy for lupus nephritis led to an increase in the proportion of patients with a complete renal response.
Stem and progenitor cells that contribute to tissue repair reside within various niches in the synovial joints of adult mammals. Understanding of the origins, identities and functions of these cells will guide the development of pro-regenerative therapeutic strategies.
Neutrophil extracellular traps might promote intraocular infiltration of effector CD4+ T cells by inducing endothelial cell senescence in autoimmune uveitis.
Findings show that the resolution of joint swelling in response to treatment with TNF inhibitors varies depending on the location of the joint in psoriatic arthritis.
Two studies provide insights into the function of TASL in the pathogenesis of systemic lupus erythematosus and highlight the therapeutic potential of targeting this protein.
Hasegawa et al. reveal how synovial joints detect systemic inflammation through specialized fenestrated blood vessels at the synovial periphery. Three distinct macrophage populations and nociceptor neurons form a sentinel unit around these vessels, coordinating immune responses and pain signalling through interleukin-1β (IL-1β) and calcitonin gene-related peptide (CGRP) signalling.
The first expert consensus recommendations for the treatment and diagnosis of adult sterile bone inflammation have been developed, in which the term ‘chronic non-bacterial osteitis’ is proposed as a disease definition. Will these recommendations pave the way for better diagnosis, management and treatment of this rare disease?
Advances in spatial omics, such as transcriptomics and proteomics, have provided vital insights into cartilage microenvironments, revealing cellular diversity, zonal organization and links between cartilage structure and function. Analysing cartilage using spatial omics could deepen the understanding of diseases such as osteoarthritis and guide the development of targeted, disease-modifying therapies.
The diagnosis, treatment and management of systemic sclerosis (SSc) remains challenging, owing to the complexity of this disease. In this Perspective, an international group of experts discuss the future of SSc research and how the advent of innovative technologies will advance research into and understanding of SSc.
Garrido-Mesa and Brown review findings from TCR profiling studies in rheumatic diseases and discuss how improved study design might help elicit information about autoreactive T cell clones and their contribution to disease pathogenesis.
The mechanisms that drive the diverse disease manifestations and increased cancer risk associated with systemic sclerosis are unclear. Investigating the genomic alterations observed in patients with systemic sclerosis could contribute towards untangling this complex disease.
This Review discusses the current evidence for the association between occupational exposures, particularly silica dust and solvents, and the risk of developing systemic autoimmune rheumatic diseases. The authors emphasize the importance of considering occupational history in the rheumatology clinic.
A mouse model that reflects Sjögren disease in humans provides insights into the role of regulatory T cells and type 1 helper T cells in disease pathogenesis.
This Review summarizes lessons learned from the use of rituximab in patients with systemic lupus erythematosus, and discusses the future of B cell targeting therapies, highlighting therapeutic options after rituximab failure and opportunities for personalized treatment.
A study implicates the Hes1–Piezo1 signalling pathway in osteocytes in the pathogenesis of glucocorticoid-induced osteoporosis and demonstrates the beneficial effects of Yoda1, a Piezo1 agonist.
This Review discusses obstacles to health care equity in rheumatic disease, including access to health care and the use of inaccurate language when labelling population groups. The authors also highlight the siloing of biological and epidemiological research in rheumatology. They conclude with recommendations for achieving equitable precision medicine.
In 2024, studies using more advanced methods to calculate the minimal important change have described how different methods and timings of estimating minimal important changes can affect the estimates.
